Mateon Therapeutics is actively seeking collaborations with corporations, academic institutions, and patient groups to advance our programs. We have a history of successful partnerships and welcome new collaboration and licensing opportunities.
Interested parties may contact:
Jeff Nelson, Vice President, Program Management
Mateon Therapeutics, Inc.
701 Gateway Blvd, Suite 210
South San Francisco, CA 94080
In collaboration with researchers from Baylor University, we are working on two project areas. One project seeks to identify additional inhibitors of tubulin polymerization that may have potential for use as cytotoxic payloads in antibody drug conjugates (ADCs). A second project is focused on the identification of novel inhibitors of the enzymes cathepsin L and K which are known to play a role in tumor cell invasion and metastases. In both areas preclinical data has been published showing activity of our agents and further evaluation is ongoing. We have an exclusive license to the worldwide development rights to all these compounds.
Gynecologic Oncology Group (GOG), part of NRG Oncology
Through a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP), Mateon supported a GOG Phase 2 trial (known as GOG-0186I) that compared CA4P (fosbretabulin) plus bevacizumab (Avastin®, which is produced and sold by Genentech/Roche) with bevacizumab alone in patients with relapsed ovarian cancer. Results from this study have been published in the Journal of Clinical Oncology. Mateon provided the investigational drug used in the trial as well as limited financial support. This trial was also supported by Genentech/Roche and the GOG.
The Christie Hospital NHS Foundation Trust
Through our history of collaborative research, Mateon has supported clinical research projects in the United Kingdom (UK) led by Cancer Research UK (CRUK) along with additional academic partners. Currently, we are supporting the PAZOFOS study (NCT02055690), which is being led by The Christie Hospital NHS Foundation Trust and coordinated by the Manchester Academic Health Science Centre, Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust, and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust). This Phase 1b/2 study is evaluating the combination of CA4P (fosbretabulin) with the tyrosine kinase inhibitor pazopanib (Votrient®) versus pazopanib alone for the treatment of advanced recurrent ovarian cancer. We are providing CA4P for use in this trial. The Phase 2 portion of the study is anticipated to start in mid 2016.
University of Kentucky, Markey Cancer Center
Continuing in our history of collaborative research, Mateon is providing investigational drug to the Markey Cancer Center for their study Study MCC-2016-08 (NCT03014297). The study is designed as a single center, open label, phase 1 clinical trial for patients with grade 1-3 gastroenteropancreatic neuroendocrine tumors. In the first part of the study, up to 15 patients will be treated with everolimus in combination with two different dosing regimens of CA4P to establish appropriate CA4P dosing levels and evaluate the safety of the drug combination. The second part of the study is designed to enroll 15 additional patients for assessment of additional safety and efficacy data. Patients enrolled in MCC-2016-088 will be treated with CA4P and everolimus for 12 weeks.
University of Arhus
We are currently working with researchers at University of Arhus to investigate preclinical models of the potential use of CA4P in immuno-oncology combined with checkpoint inhibitors. These investigators are also conducting preclinical work on our cathepsin L and K inhibitors.
University of Florida
In collaboration with clinical researchers at the University of Florida we were able to further the development of OXi4503 and have expanded that work into a multi site Phase 1b/2 study (NCT02576301).
We are also currently working with researchers at University of Florida to investigate preclinical models of the potential use of CA4P in immuno-oncology combined with checkpoint inhibitors. Additionally, these investigators are conducting preclinical work on our cathepsin L and K inhibitors.